. . . . "REMIFENTANIL"@en . . . . . . "Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist. Hence, it causes a reduction in sympathetic nervous system tone, respiratory depression and analgesia."@en . . . . " "@en . "For use during the induction and maintenance of general anesthesia."@en . "70% (bound to plasma proteins)"@en . . "Remifentanyl"@en . . . . . . "Humans and other mammals"@en . . . . . "132875-61-7"@en . . . "approved"@en . . "Remifentanil is an esterase-metabolized opioid. The carboxylic acid metabolite is essentially inactive (1/4600 as potent as remifentanil in dogs) and is excreted by the kidneys with an elimination half-life of approximately 90 minutes."@en . . . . . . "* 40 mL/min/kg [young, healthy adults]"@en . . "* 350 mL/kg * 452 \u00B1 144 mL/kg [neonates] * 223 \u00B1 30.6 mL/kg [adolescents]"@en . "Remifentanil"@en . "1-20 minutes"@en . . . . . . . . . . . . . "Remifentanil is a µ-opioid agonist with rapid onset and peak effect, and short duration of action. The µ-opioid activity of remifentanil is antagonized by opioid antagonists such as naloxone."@en . . . . . . "Jacob Mathew, J. Killgore, \"New methods for the synthesis of alfentanil, sufentanil, and remifentanil.\" U.S. Patent US20060149071, issued July 06, 2006."@en . . . . . .